Manganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

October 10, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 29, 2036

Conditions
Heart Failure With Preserved Ejection FractionType 2 Diabetes
Interventions
OTHER

Minnesota Living with Heart Failure Questionnaire

Self-administered, validated questionnaire to assess symptoms of heart failure

DIAGNOSTIC_TEST

Echocardiogram

Resting transthoracic echocardiogram to exclude valvular pathology and the assess indices of systolic and diastolic function and speckle tracking for strain

DIAGNOSTIC_TEST

Six-minute walk test

Standardised, objective assessment of exercise capacity

DIAGNOSTIC_TEST

Manganese-enhanced MRI and 31-P magnetic resonance spectroscopy

Using a 3-Tesla scanner, 31P magnetic resonance spectroscopy will be performed to obtain information regarding cardiac energetics. An intravenous infusion of manganese dipyridoxyl diphosphate (mangafodipir, MnDPDP) will be commenced at a rate of 1mL/min using a dose of 5µmol/kg (0.1mL/kg).

DIAGNOSTIC_TEST

Cardiovascular magnetic resonance scan

Scan including adenosine stress perfusion

DIAGNOSTIC_TEST

Blood tests

Full blood count, Urea and electrolytes, Liver function tests, Glucose and HbA1c, Insulin and C-peptide, NTproBNP, High sensitive troponin I, storage of plasma for future analyses

Trial Locations (1)

Unknown

RECRUITING

University of Leicester, Leicester

All Listed Sponsors
lead

University of Leicester

OTHER